AUA
Urology Times is the leading resource for urologists & allied health professionals offering clinical analysis, policy perspectives, & practical advice.
Related Articles
Increased Tobacco Taxation Associated With Decreased Consumption and Bladder Cancer Incidence | Urology Practice
Introduction:The temporal relationship between smoking exposure and bladder cancer (BC) diagnosis remains ill defined. This study aims to cross-correlate and temporally associate changes in US…
TAR-200 Shows Promise for Both Papillary-Only and CIS BCG-Unresponsive HR NMIBC – Renal and Urology News
The ongoing phase 2b SunRISe-1 study is assessing TAR-200 intravesical gemcitabine delivery in patients with BCG-unresponsive high-risk NMIBC.
UGN-102 May Be an Alternative to TURBT for Low Grade, Intermediate-Risk NMIBC – Renal and Urology News
Recurrence in patients with low-grade, intermediate-risk non-muscle invasive bladder cancer is common, and there have been a lack of alternative treatments to TURBT.
Editorial Comment | Journal of Urology
Can’t sign in? Forgot your password? If the address matches an existing account you will receive an email with instructions to reset your password. Can’t…
Abstracts – EMUC23
Submit research in oncology to be considered for EMUC23. Topics include prostate cancer, bladder cancer, RCC, testicular and penile cancers.
Cretostimogene Durability Confirmed in CIS-Containing BCG-Unresponsive NMIBC – Renal and Urology News
BOND-003 evaluated the efficacy and safety of cretostimogene grenadenorepvec, an oncolytic immunotherapy, in patients with carcinoma in situ BCG-unresponsive NMIBC.
AUA
Urology Times is the leading resource for urologists & allied health professionals offering clinical analysis, policy perspectives, & practical advice.
STEPS Meet-the-Expert Session – UROonco24
Apply now for STEPS Meet-the-Expert Session! Elevate your oncological urology expertise, connect with experts, and shape the future of scientific research.
Neal Shore, MD, on sasanlimab plus BCG for BCG-naïve NMIBC
Neal D. Shore, MD, FACS, shares the background and key findings from the phase 3 CREST trial, exploring sasanlimab plus BCG for BCG-naive NMIBC.
MP37-02 PERCEIVED BURDEN AND IMPACT OF PRIOR AUTHORIZATION ON UROLOGY PRACTICES AND CLINICAL OUTCOMES | Journal of Urology
INTRODUCTION AND OBJECTIVE:High health costs in the United States prompted health insurance companies to turn to prior authorization (PA) to reduce costs. While useful from…
